Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melphalan Flufenamide SCHEMBL20208719 | 1.00 | LMNA (0.53) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| Melphalan Flufenamide SCHEMBL24101233 | 1.00 | LMNA (0.53) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| Melphalan Flufenamide SCHEMBL29375249 | 0.99 | LMNA (0.52) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL24251989 | 0.92 | LMNA (0.47) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL6838403 | 0.92 | LMNA (0.47) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL10653540 | 0.92 | LMNA (0.47) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL24100557 | 0.91 | LMNA (0.44) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL25022336 | 0.91 | LMNA (0.43) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL22240387 | 0.89 | LMNA (0.51) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL25022665 | 0.88 | LMNA (0.40) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558337-B2 | Formulations comprising melflufen | ONCOPEPTIDES INNOVATION AB (SE) | 2026-02-24 | — | — | US | claimed |
| US-20260021067-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | ONCOPEPTIDES AB (SE) | 2026-01-22 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250333445-A1 | NOVEL POLYPEPTIDES | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-10-30 | — | — | US | claimed |
| US-20250326800-A1 | NOVEL POLYPEPTIDES | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-10-23 | — | — | US | claimed |
| US-20250281502-A1 | NEW DRUG APPLICATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-09-11 | — | — | US | claimed |
| US-12396975-B2 | Treatment of al amyloidosis with melflufen | ONCOPEPTIDES AB (SE) | 2025-08-26 | — | — | US | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| US-20250205155-A1 | FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN | ONCOPEPTIDES INNOVATION AB (SE) | 2025-06-26 | — | — | US | claimed |
| WO-2025120218-A1 | CD16A-BINDING POLYPEPTIDE | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-06-12 | — | — | WO | claimed |
| US-20220193019-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | ONCOPEPTIDES AB (SE) | 2022-06-23 | — | — | US | claimed |
| EP-3773498-B1 | LIQUID PHARMACEUTICAL FORMULATION | PROJECT PHARMACEUTICS GMBH (DE) | 2022-06-22 | — | — | EP | claimed |
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | ONCOPEPTIDES AB (SE) | 2022-06-16 | — | — | US | claimed |
| US-11344622-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2022-05-31 | — | — | US | claimed |
| CN-108685860-B | Lyophilized formulation of melphalan flufenamide | 肿瘤多肽股份公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3956032-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | Oncopeptides AB (SE) | 2022-02-23 | — | — | EP | claimed |
| US-20220047507-A1 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | ONCOPEPTIDES AB (SE) | 2022-02-17 | — | — | US | claimed |
| CN-114040798-A | Novel formulations comprising meflufen | 肿瘤多肽有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3946309-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | Oncopeptides AB (SE) | 2022-02-09 | — | — | EP | claimed |
| CN-114025753-A | Treatment of AL amyloidosis with meflufen | 肿瘤多肽有限公司 | 2022-02-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12396975-B2 | Treatment of al amyloidosis with melflufen | MME, TTR, MLLT1 | LMNA 643/4885CYP3A4 1937/4885SMN1; SMN2 412/4885 |
| US-20220193019-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | MME, TTR, MLLT1 | LMNA 643/4885CYP3A4 1937/4885SMN1; SMN2 412/4885 |
| US-20220047507-A1 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | MME, SLC43A1, SLC7A5 | LMNA 3040/4885CYP3A4 726/4885SMN1; SMN2 685/4885 |
| US-12558337-B2 | Formulations comprising melflufen | PHF8, EZH2, PHF2 | LMNA 2045/4885CYP3A4 910/4885SMN1; SMN2 831/4885 |
| US-20260021067-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | MME, MYOF, TTR | LMNA 192/4885CYP3A4 2097/4885SMN1; SMN2 119/4885 |
| US-20250205155-A1 | FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN | FUCA1, FGF2, FUCA2 | LMNA 3897/4885CYP3A4 1288/4885SMN1; SMN2 2127/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | LMNA 190/4885CYP3A4 506/4885SMN1; SMN2 2887/4885 |
| US-11344622-B2 | Lyophilized preparation of cytotoxic dipeptides | TREH, SORD, SI | LMNA 3737/4885CYP3A4 3189/4885SMN1; SMN2 2761/4885 |
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | F12, FGF2, MC3R | LMNA 3215/4885CYP3A4 337/4885SMN1; SMN2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.